Research Topics
Species | Donald TrumpSummaryAffiliation: Roswell Park Cancer Institute Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A dramatic, objective antiandrogen withdrawal response: case report and review of the literatureYiu Keung Lau
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA
J Hematol Oncol 1:21. 2008..We report a case in which a dramatic decline of serum PSA levels associated with a dramatic improvement in radiologic disease was achieved with bicalutamide discontinuation...
Vitamin D: considerations in the continued development as an agent for cancer prevention and therapyDonald L Trump
Department of Medicine, The Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Cancer J 16:1-9. 2010....
Anti-tumor activity of calcitriol: pre-clinical and clinical studiesDonald L Trump
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
J Steroid Biochem Mol Biol 89:519-26. 2004..These results demonstrate that high intermittent doses of calcitriol can be administered to patients without toxicity, that the MTD is yet to be determined and that calcitriol has potential as an anti-cancer agent...
Vitamin D deficiency and insufficiency among patients with prostate cancerDonald L Trump
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
BJU Int 104:909-14. 2009..To assess the frequency of vitamin D deficiency among men with prostate cancer, as considerable epidemiological, in vitro, in vivo and clinical data support an association between vitamin D deficiency and prostate cancer outcome...
Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancerDonald L Trump
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Cancer 106:2136-42. 2006..The combination of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) plus dexamethasone was studied based on evidence that dexamethasone potentiates the antitumor effects of calcitriol and ameliorates hypercalcemia...
Chemotherapy of prostate cancer: present and futureDonald Trump
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Curr Urol Rep 4:229-32. 2003..Randomized trials of taxane versus mitoxantrone-based therapies are underway. New agents and applications of current agents in adjuvant settings should be explored if survival in men with prostate cancer is to be improved...
Vitamin D compounds: clinical development as cancer therapy and prevention agentsDonald L Trump
Departments of Medicine and Pharmacology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Anticancer Res 26:2551-6. 2006....
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancerDonald L Trump
Roswell Park Cancer Institute, Buffalo, NY, USA
Prostate 71:1264-75. 2011..This two-part study assessed the safety and tolerability of combined treatment with zibotentan (ZD4054), a specific endothelin A receptor antagonist, plus docetaxel in patients with metastatic castration-resistant prostate cancer...
CYP24A1 inhibition enhances the antitumor activity of calcitriolJosephia R Muindi
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA
Endocrinology 151:4301-12. 2010....
Vitamin D signalling pathways in cancer: potential for anticancer therapeuticsKristin K Deeb
Department of Pharmacology, Roswell Park Cancer Institute, Buffalo, New York, USA
Nat Rev Cancer 7:684-700. 2007..Here, we outline the epidemiological, preclinical and clinical studies that support the development of 1alpha,25(OH)2D3 and vitamin D analogues as preventative and therapeutic anticancer agents...
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumorsMarwan G Fakih
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Clin Cancer Res 11:5942-9. 2005..Docetaxel, cisplatin, and capecitabine are three active chemotherapeutic agents with different mechanisms of action. This phase I study investigated the feasibility and pharmacokinetics of this combination given on a weekly schedule...
Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patientsManpreet K Chadha
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
Prostate 71:368-72. 2011..We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to influenza vaccine in prostate cancer (CaP) patients...
1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer modelsYingyu Ma
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA
Cancer 116:3294-303. 2010..The authors investigated whether 1,25D3 could enhance the antitumor activity of gemcitabine and cisplatin in bladder cancer model systems...
Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancerManpreet K Chadha
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Cancer 116:2132-9. 2010....
Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancerGeorge Wilding
Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Cancer 106:1917-24. 2006..In this pilot Phase I trial, the authors evaluated the tolerability, efficacy, and pharmacokinetics of gefitinib combined with estramustine and docetaxel in patients with HRPC...
Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cellsAdebusola A Alagbala
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, N.Y, USA
Oncology 70:483-92. 2006..These less-calcemic vitamin D analogs are as effective as calcitriol in vitro and are promising for prevention and treatment of cancer and other diseases...
Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosisGeraldine Flynn
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, N.Y, USA
Oncology 70:447-57. 2006..Thus calcitriol exerts differential effects on TDEC compared to normal cells...
Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cellsIvy Chung
Department of Molecular Pharmacology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Cancer Res 66:8565-73. 2006..These results show that TDEC were more sensitive than MDEC to the antiproliferative effects of calcitriol despite apparently normal VDR content and structure of signaling axis in both cell types...
A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumorsJosephia R Muindi
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Cancer Chemother Pharmacol 65:33-40. 2009..v.) calcitriol administered in combination with a fixed oral dose of dexamethasone and gefitinib in patients with refractory solid tumors...
Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model systemWei Dong Yu
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA
Cell Cycle 9:3022-9. 2010..Our study suggests that calcitriol and gemcitabine in combination promotes caspase-dependent apoptosis, which may contribute to increased anti-tumor activity compared to either agent alone...
Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulationJosephia R Muindi
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
Cancer Chemother Pharmacol 56:492-6. 2005..83). We conclude that the commercially available liquid 1,25-D(3) formulation offers no PK advantage over caplet formulation...
Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancerWei Luo
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Cancer Res 70:5953-62. 2010..Our findings indicate that repression of CYP24A1 gene expression in human prostate cancer cells is mediated in part by promoter DNA methylation and repressive histone modifications...
Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patientsJosephia R Muindi
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Cancer Chemother Pharmacol 59:97-104. 2007....
A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumorsMarwan G Fakih
Department of Medicine, Roswell Park Cancer Institute and The University at Buffalo, NY 14263, USA
Clin Cancer Res 13:1216-23. 2007..Therefore, we conducted a phase I study of calcitriol and gefitinib to determine the maximum tolerated dose (MTD) of this combination...
CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell linesJosephia R Muindi
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlson Streets, Buffalo, NY 14263, USA
J Steroid Biochem Mol Biol 103:334-7. 2007..These results demonstrate that calcitriol treatment modulates CYP24 splicing, and suggests that differences in CYP24 splicing are associated with different patterns of CYP24 activity...
The antitumor efficacy of calcitriol: preclinical studiesCandace S Johnson
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Anticancer Res 26:2543-9. 2006..These studies demonstrated that calcitriol has significant antiproliferative activity in a number of pre-clinical model systems and form the groundwork for on-going clinical studies investigating calcitriol as an anticancer agent...
Anti-proliferative effects of calcitriol on endothelial cells derived from two different microenvironmentsIvy Chung
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
J Steroid Biochem Mol Biol 103:768-70. 2007....
Characterization of Vitamin D insensitive prostate cancer cellsAdebusola A Alagbala
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
J Steroid Biochem Mol Biol 103:712-6. 2007..In summary, VDI cells are less responsive to the antiproliferative effects of calcitriol. Understanding Vitamin D insensitivity will further clinical development of Vitamin D compounds for prevention and treatment of CaP...
Epigenetic silencing of CYP24 in the tumor microenvironmentCandace S Johnson
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
J Steroid Biochem Mol Biol 121:338-42. 2010..These data suggest that epigenetic silencing of CYP24 modulates cellular responses to calcitriol...
1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma modelYingyu Ma
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Mol Cancer Ther 7:3047-55. 2008..The combination treatment may provide a more effective therapeutic regimen in cancer treatment...
Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriolIvy Chung
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
J Biol Chem 282:8704-14. 2007....
Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancerMarwan G Fakih
Department of Medicine, Roswell Park Cancer Institute and The University at Buffalo, Buffalo, NY 14263, USA
Int J Colorectal Dis 24:219-24. 2009..We performed a retrospective study to assess the impact of metastatic disease and chemotherapy treatment on vitamin D status in patients with colorectal cancer residing in Western New York...
Vitamin D-related therapies in prostate cancerCandace S Johnson
Cancer Metastasis Rev 21:147-58. 2002..Studies continue to define the MTD of calcitriol whichcan be safely administered on this intermittent schedule either alone or with other agents and to evaluate the mechanisms of calcitriol effects in prostate cancer...
Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series studySong Yao
Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, United States of America
PLoS ONE 6:e17251. 2011..Results from epidemiologic studies on the relationship between vitamin D and breast cancer risk are inconclusive. It is possible that vitamin D may be effective in reducing risk only of specific subtypes due to disease heterogeneity...
Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor dosesJosephia R Muindi
Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
Oncology 66:62-6. 2004..The objective of this study was to determine plasma calcitriol PK in normal mice at doses of calcitriol which are active in suppressing tumor growth...
The role of vitamin D in cancer prevention and treatmentAruna V Krishnan
Department of Medicine, Division of Endocrinology, Stanford University School of Medicine, Stanford, CA 94305 5103, USA
Endocrinol Metab Clin North Am 39:401-18, table of contents. 2010..The reasons for the lack of impressive beneficial effects in clinical trials compared with the substantial efficacy seen in preclinical models are discussed...
Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer modelSharmila Ahmed
Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
J Urol 168:756-61. 2002..02). CONCLUSIONS: These preclinical data demonstrate that calcitriol increases the antitumor activity of mitoxantrone/dexamethasone in the PC-3 model system. This combination may be efficacious for prostate cancer...
A limited sampling method for the estimation of serum calcitriol area under the curve in cancer patientsJosephia R Muindi
Center for Clinical Pharmacology, Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
J Clin Pharmacol 43:894-900. 2003..90, p = 0.0001). These results show that serum calcitriol AUC0-12 h after s.c. and p.o. calcitriol administration is accurately estimated using pretreatment and 2- and 6-hour blood samples...
Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivoIvy Chung
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Cancer Res 69:967-75. 2009..These results indicate that calcitriol-mediated antiproliferative effects on TDEC are VDR-dependent and loss of VDR can lead to abnormal tumor angiogenesis...
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapyGuru Sonpavde
Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
Cancer 115:4104-9. 2009....
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancerTomasz M Beer
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Mail Code CR 145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
Cancer Chemother Pharmacol 59:581-7. 2007..DN-101 is a new, high-dose, oral formulation of calcitriol under investigation for the treatment of cancer. We sought to evaluate the tolerability and pharmacokinetics (PK) of weekly doses of DN-101 in patients with advanced cancer...
Phenotype-specific CpG island methylation events in a murine model of prostate cancerMarta Camoriano
Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Cancer Res 68:4173-82. 2008..In conclusion, phenotype-specific hypermethylation events were associated with the overexpression of different genes and may provide new markers of prostate tumorigenesis...
Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D3-mediated apoptosis in squamous cell carcinomaYingyu Ma
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14201, USA
Cancer Res 66:8131-8. 2006..1,25D3 induces the activation of phosphatidylinositol 3-kinase/Akt, which suppresses 1,25D3-mediated apoptosis and prolongs the survival of SCC cells...
Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trialStuart Hinton
Department of Medicine, Indiana University Medical Center and The Walther Cancer Institute, Indianapolis, Indiana, USA
Cancer 97:1869-75. 2003..The VIP regimen may be considered a treatment alternative for patients with underlying pulmonary disease. In most patients with poor and intermediate-risk germ cell tumors, four cycles of BEP remain the standard therapy...
Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetateKhalid Matin
Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Cancer Chemother Pharmacol 50:179-85. 2002..Profound suppression of the pituitary-adrenal axis was also observed during the administration of megestrol acetate...
Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathwaySoo Ok Lee
Department of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Prostate 60:178-86. 2004..CONCLUSION: These results indicate that IL-6 protects androgen sensitive LNCaP cells from apoptosis induced by androgen deprivation, and Stat3 activation play an important role in IL-6-mediated anti-apoptosis in prostate cancer cells...
Interleukin-6 polymorphism is associated with more aggressive prostate cancerDongfeng Tan
Department of Pathology, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
J Urol 174:753-6. 2005..We determined the association of IL-6 polymorphism with prostate cancer progression...
Altered VDR-mediated transcriptional activity in prostate cancer stromaAlejandro A Hidalgo
Department of Urologic Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
J Steroid Biochem Mol Biol 103:731-6. 2007..These results indicate that VDR structure/function and coregulator recruitment to 1alpha,25(OH)(2)D(3) regulated genes is altered in the CaP stroma microenvironment...
Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA)Soo Ok Lee
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Prostate 66:1070-5. 2006..These findings suggest that selenium (MSC) can serve as a therapeutic agent aimed at disruption of AR signaling for prostate cancer...
Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancerManpreet K Chadha
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA
Prostate 68:1461-6. 2008..In this trial we investigated the tolerability and efficacy of fulvestrant, a pure estrogen receptor antagonist, in the treatment of castration resistant prostate cancer (CRPC)...
Does bone mineral density and knowledge influence health-related behaviors of elderly men at risk for osteoporosis?Avni Patel
Osteoporosis Prevention and Treatment Center, Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
J Clin Densitom 6:323-30. 2003..However, they were not more likely to make significant health-related lifestyle changes after obtaining the results of their bone mass...
RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cellsSoo Ok Lee
Department of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA
Prostate 60:303-9. 2004..These results demonstrate that targeting Stat3 signaling using siRNA technique may serve as a novel therapeutic strategy for treatment of prostate cancer expressing constitutively activated Stat3...
Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylationNagalakshmi Nadiminty
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Proc Natl Acad Sci U S A 103:7264-9. 2006..Furthermore, overexpression of p52 protected cells from apoptotic cell death. Thus, activation of the processing of p100 to p52 by Stat3 may represent one of the common pathways used by cancer cells to survive and escape therapy...
The case for early androgen deprivation: the data should not be ignoredSharmila Ahmed
Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 14213, USA
Urol Oncol 7:77-80. 2002
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Cancer Chemother Pharmacol 57:465-74. 2006..The pharmacokinetics of MGd were also evaluated...
Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cellsRonald J Bernardi
Department of Pharmacology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania 15213, USA
Endocrinology 143:2508-14. 2002..Thus, our work supports the hypothesis that angiogenesis inhibition plays a role in the antitumor effects of 1,25-(OH)(2)D(3)...
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancerH Barton Grossman
M.D. Anderson Cancer Center, Houston, USA
N Engl J Med 349:859-66. 2003....
Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivoSanjay K Srivastava
Department of Pharmacology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
Carcinogenesis 24:1665-70. 2003..In conclusion, the results of the present study indicate that AITC administration inhibits growth of PC-3 xenografts in vivo by inducing apoptosis and reducing mitotic activity...
Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expressionPamela A Hershberger
Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
Mol Cancer Ther 1:821-9. 2002..We propose that the increased cytotoxicity for 1,25D3/cisplatin results from cisplatin enhancement of 1,25D3-induced apoptotic signaling through MEKK-1...
Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group studyAndrea N Leaf
Department of Hematology/Oncology 111D, Veterans Affairs Medical Center, 800 Poly Place, Brooklyn, NY 11209, USA
Med Oncol 20:137-46. 2003..Failure-free survival duration did reach statistical significance in the combined-therapy group (p = 0.012), although the actual durations were short (2.6-3.2 mo). There was no difference in overall survival between the two groups...
Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxelJosephia R Muindi
Center for Clinical Pharmacology and Cancer Institute, University of Pittsburgh, PA 15213, USA
Clin Pharmacol Ther 72:648-59. 2002..An additional goal was to evaluate the relationship between calcitriol dose and hypercalcemia...
Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trialTheodore F Logan
University of Pittsburgh, Pennsylvania 15260, USA
Cancer Chemother Pharmacol 50:433-44. 2002....
Glucocorticoids and treatment of prostate cancer: a preclinical and clinical reviewMarwan Fakih
Department ofMedicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Urology 60:553-61. 2002
Vitamin D receptor: a potential target for interventionCandace S Johnson
Department of Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
Urology 60:123-30; discussion 130-1. 2002..Studies continue to define the MTD of calcitriol on this intermittent schedule, either alone or with other agents, and to evaluate the mechanisms of calcitriol effects in prostate cancer models...
Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cellsDong Xiao
Department of Pharmacology and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
Mol Cancer Ther 3:567-75. 2004..Furthermore, the results of the present study point toward involvement of both caspase-8- and caspase-9-mediated pathways in apoptosis induction by PEITC...
Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2Dong Xiao
Department of Pharmacology and Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Oncogene 23:5594-606. 2004..In conclusion, our data point towards important roles for Bcl-2, JNK and ERK in DATS-induced apoptosis in human prostate cancer cells...
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapySusan L Greenspan
Divisions of Geriatric Medicine and Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
J Clin Oncol 26:4426-34. 2008..Our objective was to examine changes in bone density and turnover with sustained, discontinued, or delayed oral bisphosphonate therapy in men receiving ADT...
Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancerTomasz M Beer
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, 97239, USA
Clin Cancer Res 11:7794-9. 2005..In this dose escalation study, we sought to evaluate the tolerability and pharmacokinetics of a single oral dose of DN-101, a high-dose calcitriol formulation...
Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen speciesShivendra V Singh
Department of Pharmacology and University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
J Biol Chem 280:19911-24. 2005....
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trialMaha H A Hussain
University of Michigan, Ann Arbor, USA
J Clin Oncol 25:2218-24. 2007....
Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignanciesXueyu Chen
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Room 5 221A, 610 University Ave, Toronto, ON, Canada, M5G 2M9
Cancer Chemother Pharmacol 55:237-43. 2005....
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumorsLaura L Jung
Molecular Therapeutics and Drug Discovery Program, University of Pittsburgh Cancer Institute, PA 15213, Pittsburgh, USA
Cancer Chemother Pharmacol 54:487-96. 2004..97, respectively. The recovery of 9NC and 9AC in the urine was <15%. CONCLUSIONS: There was significant interpatient and intrapatient variability in the disposition of 9NC and 9AC. 9NC and 9AC undergo primarily nonrenal elimination...
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumorsWilliam C Zamboni
Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
Clin Cancer Res 10:5058-64. 2004..In an effort to increase the dose administered per day and determine whether the daily dose or number of days of treatment influence toxicity, we performed a Phase I study of 9NC using intermittent schedules of administration...
Bladder cancer. Clinical guidelines in oncologyJames E Montie
J Natl Compr Canc Netw 4:984-1014. 2006
Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosisDong Xiao
Department of Pharmacology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, PA 15213, USA
Carcinogenesis 24:891-7. 2003..In conclusion, it seems reasonable to hypothesize that AITC, and possibly other ITCs, may find use in the treatment of human prostate cancers...
Elevated seroprevalence of human herpesvirus 8 among men with prostate cancerLinda J Hoffman
Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
J Infect Dis 189:15-20. 2004..253; 95% CI, 0.77-3.54).Conclusions. HHV-8 seropositivity is elevated among men with prostate cancer compared with control subjects, which suggests that HHV-8 plays a role in the development of prostate cancer...
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancerSusan L Greenspan
Osteoporosis Prevention and Treatment Center, University of Pittsburgh, Kaufmann Medical Building, Suite 1110, 3471 Fifth Avenue, Pittsburgh, Pennsylvania 15213 3221, USA
J Clin Endocrinol Metab 90:6410-7. 2005..Although androgen deprivation therapy (ADT) for prostate cancer is associated with bone loss, little is known about when this bone loss occurs...
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trialSusan L Greenspan
University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Ann Intern Med 146:416-24. 2007..Androgen deprivation therapy (ADT) in men with prostate cancer is associated with bone loss and fractures...
Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patientsRamesh K Ramanathan
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Clin Oncol 20:4313-8. 2002..To determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) would improve response to influenza vaccination in cancer patients...
Peroxisome proliferator-activated receptor-gamma polymorphism, body mass and prostate cancer risk: evidence for gene-environment interactionJoseph M Zmuda
Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
Oncology 70:185-9. 2006..Peroxisome proliferator-activated receptor (PPAR)-gamma has been implicated in prostate cancer. In the present case-control study, we tested if a common Pro12Ala polymorphism in PPAR-gamma is associated with the risk of prostate cancer...
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancersRamesh K Ramanathan
Molecular Therapeutics Drug Discovery Program, Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15232, USA
Clin Cancer Res 11:3385-91. 2005..We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics...
High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer SurveyClareann H Bunker
Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
Cancer Epidemiol Biomarkers Prev 11:726-9. 2002..These data support the hypothesis that populations of African descent share genetic and/or lifestyle factors that contribute to their elevated risk for prostate cancer...
Research Grants
- Vitamin D in Prostate Cancer: Tumor Vasculature EffectsDonald Trump; Fiscal Year: 2006....
- Evaluation of CYP24 as a Target for Enhancing Vitamin D*Donald Trump; Fiscal Year: 2006..D receptor expression, expression of apoptosis markers whether a relationship exists between modulation of these effects in vitro on tumor cells and a significant antitumor response in vivo in prostate, pancreatic and lung cancer models ..
- Enhancing the Safety of Research ParticipantsDonald Trump; Fiscal Year: 2003..abstract_text> ..
- Implementation of Data Safety Monitoring Plan (DSMP)Donald Trump; Fiscal Year: 2002..abstract_text> ..
